Cryoport Supports NeoStem’s Intus Study for the Treatment of Metastatic Melanoma

April 29, 2015

Lake Forest, CA, April 29, 2015 - Cryoport, Inc. (OTCBB: CYRX) (“Company”), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers and reproductive medicine, today announced that the Company is supporting NeoStem, Inc.’s (NASDAQ: NBS) Intus Study to evaluate its lead cancer immunotherapy, NBS20, for the treatment of metastatic melanoma.

Read More

Tags: Frozen Shipping, Biopharmaceutical Cold Chain, NeoStem, Metastatic melanoma, Intus Study